[1]
|
Chonga, Q.-Y., Koka, Z.-H., Bui, N.-L.-C., Xiang, X., Wong, A.L.-A., Yong, W.-P., Sethi, G., Lobie, P.E., Wang, L.W. and Goh, B.-C. (2020) A Unique CDK4/6 Inhibitor: Current and Future Therapeutic Strategies of Abemaciclib. Pharmacological Research, 156, Article ID: 104686. https://doi.org/10.1016/j.phrs.2020.104686
|
[2]
|
Wu, P., Nielsen, T.E. and Clausen, M.H. (2015) FDA-Approved Small-Molecules Kinases Inhibitors. Trends in Pharmacological Sciences, 36, 422-439.
https://doi.org/10.1016/j.tips.2015.04.005
|
[3]
|
CenterWatch. 2001 FDA Approved Drugs.
https://www.centerwatch.com/drug-information/fda-approved-drugs/year/2001
|
[4]
|
Carles, F., Bourg, S., Meyer, C. and Bonnet, P. (2018) PKIDB: A Curated, Annotated and Updated Database of Protein Kinases in Clinical Trials. Molecules, 23, 908-926.
https://doi.org/10.3390/molecules23040908
|
[5]
|
FDA Approves Palbociclib for Metastatic Breast Cancer.
http://www.onclive.com/web-exclusives/FDA-Approves-Palbociclib-for-Metastatic-Breast-Cancer
|
[6]
|
Lu, J. (2015) Palbociclib: A First-in-Class CDK4/CDK6 Inhibitor for the Treatment of Hormone-Receptor Positive Advanced Breast Cancer. Journal of Hematology & Oncology, 8, 98-100. https://doi.org/10.1186/s13045-015-0194-5
|
[7]
|
Finn, R.S., Crown, J-P., Lang, I., Boer, K., Bondarenko, I.M., Kulyk, S.O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., Shparyk, Y., Thummala, A.R., Voytko, N.L., Fowst, C., Huang, X., Kim, S.T., Randolph, S. and Slamon, D.J. (2015) The Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib in Combination with Letrozole versus Letrozole Alone as First-Line Treatment of Oestrogen Receptor-Positive, HER2-Negative, Advanced Breast Cancer (PALOMA-1/TRIO-18): A Randomised Phase 2 Study. The Lancet Oncology, 16, 25-35.
https://doi.org/10.1016/S1470-2045(14)71159-3
|
[8]
|
Porati, M. and Marzaro, G. (2019) Third-Generation CDK Inhibitors: A Review on the Synthesis and Binding Modes of Palbociclib, Ribociclib and Abemaciclib. European Journal of Medicinal Chemistry, 172, 149-153.
https://doi.org/10.1016/j.ejmech.2019.03.064
|
[9]
|
Study of Efficacy and Safety of LEE011 in Postmenopausal Women with Advanced Breast Cancer (MONALEESA-2). ClinicalTrials.gov. Clinical Trial Number NCT01958021. https://www.clinicaltrials.gov/show/NCT01958021
|
[10]
|
Abemaciclib Receives FDA Approval for Certain Metatstatic Breast Cancers.
http://www.oncotherapynetwork.com/breast-cancer-targets/abemaciclib-receives-fda-approval-certain-metastatic-breast-cancers
|
[11]
|
Hurvitz, S.A., Martin, M., Press, M.F., Chan, D., Fernandez-Abad, M., Petru, E., Rostorfer, R., Guarneri, V., Huang, C-S., Wijayawardana, B.S.S., Brahmachary, M., Ebert, P.J., Hossain, A., Liu, J., Abel, A., Aggarwal, A., Jansen, V.M. and Slamon, D.J. (2020) Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HRt/HER2 Breast Cancer. Clinical Cancer Research, 26, 566-580.
https://doi.org/10.1158/1078-0432.CCR-19-1425
|
[12]
|
Shapiro, G., Rosen, L.S., Tolcher, A.W., Goldman, J.W., Gandhi, L., Papadopoulos, K.P., Tolaney, S.M., Beeram, M., Rasco, D.W., Kulanthaivel, P., Li, Q., Hu, T., Cronier, D., Chan, E.M., Flaherty, K., Wen, P.Y. and Patnaik, A. (2013) A First-in-Human Phase I Study of the CDK4/6 Inhibitor, LY2835219, for Patients with Advanced Cancer. Journal of Clinical Oncology, 31, 2500.
https://doi.org/10.1200/jco.2013.31.15_suppl.2500
|
[13]
|
Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell Lymphoma.
https://ash.confex.com/ash/2014/webprogram/Paper72259.html
|
[14]
|
FDA’s Breakthrough Therapy Designation to Abemaciclib for Breast Cancer. Oncology Times LWW Journals.
https://journals.lww.com/oncology-times/blog/fdaactionsandupdates/pages/post.aspx?PostID=119
|
[15]
|
Dickson, M.A. (2014) Molecular Pathways: CDK4 Inhibitors for Cancer Therapy. Clinical Cancer Research, 13, 3379-3383.
https://doi.org/10.1158/1078-0432.CCR-13-1551
|
[16]
|
Gelbert, L.M., Cai, S., Lin, X., Sanchez-Martinez, C., del Prado, M., Lallena, M.J., Torres, R., Ajamie, R.T., Wishart, G.N., Flack, R.S., Neubauer, B.L., Young, J., Chan, E.M., Iversen, P., Cronier, D., Kreklau, E. and de Dios, A. (2014) Preclinical Characterization of the CDK4/6 Inhibitor LY2835219: In-Vivo Cell Cycle-Dependent/Independent Anti-Tumor Activities Alone/In Combination with Gemcitabine. Investigational New Drugs, 32, 825-837. https://doi.org/10.1007/s10637-014-0120-7
|
[17]
|
Shapiro, G., Rosen, L.S., Tolcher, A.W., Goldman, J.W., Gandhi, L., Papadopoulos, K.P., Tolaney, S.M., Beeram, M., Rasco, D.W., Kulanthaivel, P., Li, Q., Hu, T., Cronier, D., Chan, E.M., Flaherty, K., Wen, P.Y. and Patnaik, A. (2014) Clinical Activity of LY2835219, a Novel Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Metastatic Breast Cancer. AACR Annual Meeting 2014, San Diego, 5-9 April 2014, Abstract CT232.
|
[18]
|
Sledge Jr., G.W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N.A., Kaufman, P.A., Koh, H., Grischke, E.-M., Frenzel, M., Lin, Y., Barriga, S., Smith, I.C., Bourayou, N. and Antonio Llombart-Cussac, A. (2017) MONARCH 2: Abemaciclib in Combination with Fulvestrant in Women with HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. Journal of Clinical Oncology, 35, 2875-2884.
https://doi.org/10.1200/JCO.2017.73.7585
|
[19]
|
Goetz, M.P., Toi, M., Campone, M., Sohn, J., Paluch-Shimon, S., Huober, J., Park, I.H., Trédan, O., Chen, S.-C., Manso, L., Freedman, O.C., Jaliffe, G.G., Forrester, T., Frenzel, M., Barriga, S., Smith, I.C., Bourayou, N. and Di Leo, A. (2017) MONARCH 3: Abemaciclib as Initial Therapy for Advanced Breast Cancer. Journal of Clinical Oncology, 35, 3638-3646. https://doi.org/10.1200/JCO.2017.75.6155
|
[20]
|
Johnston, S., Martin, M., Di Leo, A., Im, S.-A., Awada, A., Forrester, T., Frenzel, M., Hardebeck, M.C., Cox, J., Barriga, S., Toi, M., Iwata, H. and Goetz, M.P. (2019) MONARCH 3 Final PFS: A Randomized Study of Abemaciclib as Initial Therapy for Advanced Breast Cancer. Nature Breast Cancer, 5, Article No. 5.
https://doi.org/10.1038/s41523-018-0097-z
|
[21]
|
O’Leary, B., Finn, R.S. and Turner, N.C. (2016) Treating Cancer with Selective CDK4/6 Inhibitors. Nature Reviews Clinical Oncology, 13, 417-430.
https://doi.org/10.1038/nrclinonc.2016.26
|
[22]
|
Lim, E., Beith, J., Frances Boyle, F., de Boer, R., Hui, R., Mc Carthy, N., Redfern, A., Wade, T. and Woodward, N. (2018) Emerging Data and Future Directions for CDK4/6 Inhibitor Treatment of Patients with Hormone Receptor Positive HER2-Non-Amplified Metastatic Breast Cancer. The Asia-Pacific Journal of Clinical Oncology, 14, 12-21. https://doi.org/10.1111/ajco.13065
|
[23]
|
Coates, D.A., Gelbert, L.M., Knobeloch, J.M., De Dios Managa, A., De Prado Gonzalez, A., Filadelfa Del Prado Catalina, M., Garcia Parades, M.C., Martin de la Nava, M., Martin Ortega Finger, M.D., Martinez-Perez, J.A., Mateo Herranz, A.I., Perez Martinez, C. and Sanchez Martinez, C. (2010) Protein Kinase Inhibitors. US Patent 2010/0160340 A1.
|
[24]
|
Frederick, M.O. and Kjell, D.P. (2015) A Synthesis of Abemaciclib Utilizing a Leuckart-Wallach Reaction. Tetrahedron Letters, 56, 949-951.
https://doi.org/10.1016/j.tetlet.2014.12.082
|
[25]
|
Frederick, M.O., Pietz, M.A., Kjell, D.P., Richey, R.N., Tharp, G.A., Touge, T., Yokoyama, N., Michio Kida, M. and Matsuo, T. (2017) Development of a Leuckart-Wallach Reaction in Flow for the Synthesis of Abemaciclib. Organic Process Research & Development, 21, 1447-1451.
https://doi.org/10.1021/acs.oprd.7b00234
|
[26]
|
Merritt, J.M., Andiappan, M., Pietz, M.A., Richey, R.N., Sullivan, K.A. and Kjell, D.P. (2016) Mitigating the Risk of Coprecipitation of Pinacol during Isolation from Telescoped Miyaura Borylation and Suzuki Couplings Utilizing Boron Pinacol Esters: Use of Modeling for Process Design. Organic Process Research & Development, 20, 178-188. https://doi.org/10.1021/acs.oprd.5b00324
|
[27]
|
Tolaney, S.M., Lin, N.U., Thornton, D., Klise, S., Costigan, T.M. and Turner, K. (2017) Abemaciclib for the Treatment of Brain Metastases (BM) Secondary to Hormone Receptor Positive (HR+), HER2 Negative Breast Cancer. Journal of Clinical Oncology, 35, 1019-1019. https://doi.org/10.1200/JCO.2017.35.15_suppl.1019
|
[28]
|
Martin, M., Hurvitz, S.A., Chan, D., Fernandez-Abad, M., Petru, E., Rostorfer, R., Guarneri, V., Huang, C.-S., Press, M.F., Costigan, T.M., Caldwell, C.W., Wijayawardana, S., Turner, P.K., Barriga, S. and Slamon, D.J. (2018) Abstract PD5-01: Final Results of NeoMONARCH: A Phase 2 Neoadjuvant Study of Abemaciclib in Post-Menopausal Women with Hormone Receptor Positive (HR+), HER2 Negative Breast Cancer (BC). Cancer Research, 78, PD5-01.
https://doi.org/10.1158/1538-7445.SABCS17-PD5-01
|
[29]
|
Martin, J.M. and Goldstein, L.J. (2018) Profile of Abemaciclib and Its Potential in the Treatment of Breast Cancer. OncoTargets and Therapy, 11, 5253-5259.
https://doi.org/10.2147/OTT.S149245
|
[30]
|
McCartney, A., Moretti, E., Sanna, G., Pestrin, M., Risi, E., Malorni, L., Biganzoli, L. and Di Leo, A. (2018) The Role of Abemaciclib in Treatment of Advanced Breast Cancer. Therapeutic Advances in Medical Oncology, 10, 1-14.
https://doi.org/10.1177/1758835918776925
|
[31]
|
Corona, S.P. and Generali, D. (2018) Abemaciclib: A CDK4/6 Inhibitor for the Treatment of HR+/HeR2− Advanced Breast Cancer. Drug Design, Development and Therapy, 12, 321-330. https://doi.org/10.2147/DDDT.S137783
|